Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial

Trials

Marc H Gorelick⁸  David Schnadower⁹  Karen Black¹  David W Johnson⁷  Ron Goeree⁴  Andrew R Willan³  Serge Gouin^1,12  Ken J Farion²  Philip M Sherman⁵  Suzanne Schuh^1,10  Sarah Williamson-Urquhart^1,11  Stephen B Freedman⁶ 

[1] Division of Pediatric Emergency Medicine, University of British Columbia, BC Children’s Hospital, 4480 Oak St, Vancouver, BC V6H3N1, Canada;Emergency Department, Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON K1H8L1, Canada;Program in Child Health Evaluative Sciences, SickKids Research Institute, Dalla Lana School of Public Health, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada;PATH Research Institute, St. Joseph's Healthcare Hamilton, Department of Clinical Epidemiology and Biostatistics, McMaster University, 25 Main Street West, Suite 2000, Hamilton, ON L8P1H1, Canada;Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada;Sections of Paediatric Emergency Medicine and Gastroenterology, Alberta Children’s Hospital, Alberta Children’s Hospital Research Institute, University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada;Departments of Pediatrics and Physiology and Pharmacology, Faculty of Medicine, Alberta Children’s Hospital Research Institute, University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada;Department of Pediatrics, Medical College of Wisconsin, Children’s Hospital of Wisconsin, 8915 W. Connell Ave., P.O. Box 1997, Milwaukee, WI 53226, USA;Division of Pediatric Emergency Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8116, St. Louis 63110MO, USA;Division of Paediatric Emergency Medicine, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada;Paediatric Emergency Research Team, Alberta Children’s Hospital, University of Calgary, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada;Division of Paediatric Emergency Medicine, Department of Pediatrics, Centre Hospitalier Universitaire Ste-Justine, Université de Montréal, 3175 Côte-Sainte-Catherine, Montréal, Québec H3T1C5, Canada

关键词: Immunoglobulin A;    Adverse effects;    Randomized controlled trial;    Gastroenteritis;    Pediatrics;    Emergencies;    Probiotics;   

Others  :  806187
DOI  :  10.1186/1745-6215-15-170

 received in 2014-01-21, accepted in 2014-04-29,  发布年份 2014

【 摘 要 】

Background

The burden of acute gastroenteritis on children and their families continues to be enormous. Probiotics, defined as viable microbial preparations that have a beneficial effect on the health of the host, represent a rapidly expanding field. Although clinical trials in children with gastroenteritis have been performed, most have significant flaws, and guidelines do not consistently endorse their use.

Methods/Design

PROGUT is a randomized, placebo-controlled, double-blind, five-center, Canadian, emergency department trial. Children aged 3 months to 48 months who present between November 2013 and June 2017 with <72 hours of gastroenteritis symptoms will be assessed for eligibility. A total of 886 children will be randomized (1:1 allocation via an internet based, third party, randomization service) to receive 5 days of a combination probiotic agent (Lactobacillus rhamnosus and L. helveticus) or placebo. All participants, caregivers, and outcome assessors will be blinded to group assignment. The study includes three key outcomes: 1) clinical - the development of moderate to severe disease following an emergency department (ED) evaluation that employs a validated clinical score (Modified Vesikari Scale); 2) safety - side effect; and 3) mechanism - fecal secretory immunoglobulin A levels.

Discussion

Definitive data are lacking to guide the clinical use of probiotics in children with acute gastroenteritis. Hence, probiotics are rarely prescribed by North American physicians. However, the following current trends obligate an urgent assessment: 1) probiotics are sold as food supplements, and manufacturers can encourage their use while their relevance has yet to be established; 2) North American and European government agencies remain concerned about their value and safety; 3) some institutions are now recommending the routine use of probiotics; and 4) parents of affected children are often providing probiotics. With probiotic consumption increasing in the absence of solid evidence, there is a need to conduct this definitive trial to overcome the limitations of prior work in this field.

Trial registration

ClinicalTrials.gov: NCT01853124; first registered 9 May 2013.

【 授权许可】

   
2014 Freedman et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM: Foodborne illness acquired in the United States–unspecified agents. Emerg Infect Dis 2011, 17:16-22.
• [2]Jones TF, McMillian MB, Scallan E, Frenzen PD, Cronquist AB, Thomas S, Angulo FJ: A population-based estimate of the substantial burden of diarrhoeal disease in the United States; FoodNet, 1996–2003. Epidemiol Infect 2007, 135:293-301.
• [3]Senecal M, Brisson M, Lebel MH, Yaremko J, Wong R, Gallant LA, Garfield HA, Ableman DJ, Ward RL, Sampalis JS, Mansi JA, group Ms: Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): a prospective community-based study. Can J Infect Dis Med Microbiol 2008, 19:397-404.
• [4]Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW: Substantial morbidity for hospitalized children with community-acquired rotavirus infections, 2005–2007 IMPACT surveillance in Canadian hospitals. Pediatr Infect Dis J 2010, 29:879-882.
• [5]Mast TC, DeMuro-Mercon C, Kelly CM, Floyd LE, Walter EB: The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009, 9:11. BioMed Central Full Text
• [6]Salminen S, Ouwehand A, Benno Y, Lee YK: Probiotics: how should they be defined? Trend Food Sci Technol 1999, 10:107-110.
• [7]Van Niel CW, Feudtner C, Garrison MM, Christakis DA: Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002, 109:678-684.
• [8]Szajewska H, Mrukowicz JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33(Suppl 2):S17-S25.
• [9]Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D: Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25:871-881.
• [10]Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ: Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002, 47:2625-2634.
• [11]Allen SJ, Martinez EG, Gregorio GV, Dans LF: Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010, 11:CD003048.
• [12]Das RR: Should probiotics be used in the treatment of acute childhood diarrhea? J Clin Gastroenterol 2012, 46:526-527.
• [13]Weizman Z: Probiotics use in childhood acute diarrhea: a web-based survey. J Clin Gastroenterol 2011, 45:426-428.
• [14]D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ: Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ (Clinical Research Ed) 2002, 324:1361.
• [15]Reid G, Jass J, Sebulsky MT, McCormick JK: Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003, 16:658-672.
• [16]Li ST, Klein EJ, Tarr PI, Denno DM: Parental management of childhood diarrhea. Clin Pediatr (Phila) 2009, 48:295-303.
• [17]Vernacchio L, Vezina RM, Mitchell AA, Lesko SM, Plaut AG, Acheson DW: Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J 2006, 25:2-7.
• [18]Freedman SB, Gouin S, Bhatt M, Black KJ, Johnson D, Guimont C, Joubert G, Porter R, Doan Q, van Wylick R, Schuh S, Atenafu E, Eltorky M, Cho D, Plint A: Prospective assessment of practice pattern variations in the treatment of pediatric gastroenteritis. Pediatrics 2011, 127:e287-e295.
• [19]Freedman SB, Sivabalasundaram V, Bohn V, Powell EC, Johnson DW, Boutis K: The treatment of pediatric gastroenteritis: a comparative analysis of pediatric emergency physicians’ practice patterns. Acad Emerg Med 2011, 18:38-45.
• [20]Katan MB: Why the European Food Safety Authority was right to reject health claims for probiotics. Benef Microbes 2012, 3:85-89.
• [21]Vero V, Gasbarrini A: The EFSA health claims ‘learning experience’. Int J Food Sci Nutr 2012, 63(Suppl 1):14-16.
• [22]Flynn A: Scientific substantiation of health claims in the EU. Proc Nutr Soc 2012, 71:120-126.
• [23]Heimbach JT: Health-benefit claims for probiotic products. Clin Infect Dis 2008, 46(Suppl 2):S122-S124. discussion S144-S151
• [24]Markets and Markets: Global Probiotics Market Worth US$32.6 Billion by 2014. Available at: http://www.prnewswire.com/news-releases/marketsandmarkets-global-probiotics-market-worth-us326-billion-by-2014-62565667.html; webcite Accessed May 9, 2014. Wilmington, DE
• [25]Coppens P, da Silva MF, Pettman S: European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety. Toxicology 2006, 221:59-74.
• [26]Saldanha LG: US Food and Drug Administration regulations governing label claims for food products, including probiotics. Clin Infect Dis 2008, 46(Suppl 2):S119-S121.
• [27]von Wright A: Regulating the safety of probiotics–the European approach. Curr Pharm Des 2005, 11:17-23.
• [28]Parker MW, Schaffzin JK, Lo Vecchio A, Yau C, Vonderhaar K, Guiot A, Brinkman WB, White CM, Simmons JM, Gerhardt WE, Kotagal UR, Conway PH: Rapid adoption of Lactobacillus rhamnosus GG for acute gastroenteritis. Pediatrics 2013, Mar, 131(Suppl 1):S96-S102.
• [29]Guyatt G, Montori V, Devereaux PJ, Schunemann H, Bhandari M: Patients at the center: in our practice, and in our use of language. ACP J Club 2004, 140:A11-A12.
• [30]Guandalini S: Probiotics for children with diarrhea: an update. J Clin Gastroenterol 2008, 42(Suppl 2):S53-S57.
• [31]Vandenplas Y, Salvatore S, Vieira M, Devreker T, Hauser B: Probiotics in infectious diarrhoea in children: are they indicated? Eur J Pediatr 2007, 166:1211-1218.
• [32]Coffin SE, Elser J, Marchant C, Sawyer M, Pollara B, Fayorsey R, Nelson L, Lawley D, Goveia M, Stek J, Hille D, DiNubile MJ: Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr Infect Dis J 2006, 25:584-589.
• [33]Szymanski H, Pejcz J, Jawien M, Chmielarczyk A, Strus M, Heczko PB: Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains–a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:247-253.
• [34]Nixon AF, Cunningham SJ, Cohen HW, Crain EF: The effect of Lactobacillus GG on acute diarrheal illness in the pediatric emergency department. Pediatr Emerg Care 2012, 28:1048-1051.
• [35]Walker WA: Mechanisms of action of probiotics. Clin Infect Dis 2008, 46(Suppl 2):S87-S91. discussion S144-S151
• [36]Sarker SA, Fuchs GJ: The role of probiotics in the treatment and prevention of infectious diarrhea in children. In Proboitics in Pediatric Medicine. Edited by Michail S, Sherman PM. Totowa, NJ: Humana Press; 2009.
• [37]World Health Organization: The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers. WHO Press: Geneva, Switzerland; 2005. [4th revision]
• [38]Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, Rincon C, Hortal J, Pelaez T: Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005, 40:1625-1634.
• [39]Riquelme AJ, Calvo MA, Guzman AM, Depix MS, Garcia P, Perez C, Arrese M, Labarca JA: Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003, 36:41-43.
• [40]Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659.
• [41]Tlaskal P, Schramlova J, Kokesova A, Adamus J, Bubakova D, Kocnarova N, Kopecka K, Muckova M, Pacovska J, Sladkova E: Probiotics in the treatment of diarrheal disease of viral etiology in children. NAFAS 2005, 3:25-28.
• [42]Szajewska H, Setty M, Mrukowicz J, Guandalini S: Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006, 42:454-475.
• [43]Johnston BC, Supina AL, Vohra S: Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006, 175:377-383.
• [44]Freedman SB, Eltorky M, Gorelick M: Pediatric Emergency Research Canada Gastroenteritis Study G Evaluation of a gastroenteritis severity score for use in outpatient settings. Pediatrics 2010, 125:e1278-e1285.
• [45]Fruhwirth M, Heininger U, Ehlken B, Petersen G, Laubereau B, Moll-Schuler I, Mutz I, Forster J: International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection. Pediatr Infect Dis J 2001, 20:784-791.
• [46]Givon-Lavi N, Greenberg D, Dagan R: Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine 2008, 26:5798-5801.
• [47]Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Sáez-Llorens X, et al.: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
• [48]Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM: Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
• [49]Ruuska T, Vesikari T: Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22:259-267.
• [50]Iturriza Gomara M, Simpson R, Perault AM, Redpath C, Lorgelly P, Joshi D, Mugford M, Hughes CA, Dalrymple J, Desselberger U, Gray J: Structured surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common viral gastroenteric pathogens. Epidemiol Infect 2008, 136:23-33.
• [51]Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD: Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 2012, 30(Suppl 1):A79-A85.
• [52]Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF: Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine 2012, 30(Suppl 1):A52-A60.
• [53]Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM: Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine 2012, 30(Suppl 1):A24-A29.
• [54]Huppertz HI, Forster J, Heininger U, Roos R, Neumann HU, Hammerschmidt T: The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr 2008, 47:363-371.
• [55]Diez-Domingo J, Patrzalek M, Cantarutti L, Arnould B, Meunier J, Soriano-Gabarro M, Meyer N, Pircon JY, Holl K: The impact of childhood acute rotavirus gastroenteritis on the parents’ quality of life: prospective observational study in European primary care medical practices. BMC Pediatr 2012, 12:58. BioMed Central Full Text
• [56]Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH: Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand 1991, 80:173-180.
• [57]Joensuu J, Koskenniemi E, Pang XL, Vesikari T: Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997, 350:1205-1209.
• [58]Cicek C, Karatas T, Altuglu I, Koturoglu G, Kurugol Z, Bilgic A: Comparison of ELISA with shell vial cell culture method for the detection of human rotavirus in fecal specimens. New Microbiol 2007, 30:113-118.
• [59]Binka FN, Anto FK, Oduro AR, Awini EA, Nazzar AK, Armah GE, Asmah RH, Hall AJ, Cutts F, Alexander N, Brown D, Green J, Gray J, Iturriza-Gomara M: Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Trop Med Int Health 2003, 8:840-846.
• [60]Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L: Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997, 25:516-519.
• [61]Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T: A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991, 88:90-97.
• [62]Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Moller PL, Pedersen P, Tvede M, Weyrehter H, Valerius NH, Paerregaard A: Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J 2002, 21:411-416.
• [63]Schnadower D, Tarr PI, Gorelick MH, O’Connell K, Roskind CG, Powell EC, Rao J, Bhatt S, Freedman SB: Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr 2013, 57:514-519.
• [64]Fleiss J: Statistical Methods for Rates and Proportions. 2nd edition. New York: John Wiley & Sons; 1981.
• [65]Freedman SB, Adler M, Seshadri R, Powell EC: Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 2006, 354:1698-1705.
• [66]Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, Mitton C, Gouin S, Bhatt M, Joubert G, Black KJ, Turner T, Whitehouse S, Klassen TP: Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 2009, 360:2079-2089.
• [67]Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, Ruddy RM, Malik B, Nelson KA, Bregstein JS, Brown KM, Denenberg MN, Lillis KA, Cimpello LB, Tsung JW, Borgialli DA, Baskin MN, Teshome G, Goldstein MA, Monroe D, Dean JM, Kuppermann N: A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007, 357:331-339.
• [68]Scholtens PA, Alliet P, Raes M, Alles MS, Kroes H, Boehm G, Knippels LM, Knol J, Vandenplas Y: Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides. J Nutr 2008, 138:1141-1147.